The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Human Immunodeficiency Virus

Human Immunodeficiency Virus (HIV) continues to be a major global public health issue, having claimed more than 35 million lives as of 2018. In 2017, 940 000 people died from HIV-related causes globally. There were approximately 36.9 million people living with HIV by the end of 2017, with 1.8 million people becoming newly infected in 2017 globally (WHO).

To support continuing research into HIV, The Native Antigen Company have developed a panel of recombinant proteins and antibodies for different strains of HIV.

HIV Background

The Native Antigen Company offers untagged HIV-1 glycoprotein gp140 group M subtypes A, B, C, CRF01-AE, group O, and HIV-2 glycoprotein gp140, enabling a new generation of diagnostic assays and structural studies.

The viral entry receptor for HIV-1 and HIV-2 is the Envelope protein gp160, a transmembrane glycoprotein featuring the mature glycoprotein gp120 and the transmembrane protein gp41. Both neutralising and non-neutralising patient antibodies are targeted against gp160, making this protein an exciting diagnostic and vaccine target. gp160 is synthesised as a polyprotein and cleaved by the host-resident protease furin (Checkley et al., 2011). Removal of the intravirion and transmembrane domains allows for production of a soluble secreted version of gp160 termed gp140.

Read more about advantages of our novel HIV antigens portfolio in the blog: New Tools for HIV Diagnosis



Checkley, M.A., Luttge, B.G. and Freed, E.O. (2011) ‘HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation’, Journal of Molecular Biology, 410(4), pp. 582–608. doi:10.1016/j.jmb.2011.04.042.

HIV Antigens

The Native Antigen Company offers a panel of recombinant HIV gp120 proteins, expressed in our mammalian cell system to ensure correct folding and glycosylation. Our HIV antigens are available from different HIV-1 sub-types, allowing researchers to study the differing behaviours of the sub-types and associated activity of a range of proteins.

HIV Antibodies

The Native Antigen Company offers a selection of HIV antibodies allowing you to pursue a broad range of R&D activities, including assay development and vaccine research.

Check out our Blog!

New Tools for HIV Diagnosis: Enabling a new generation of Human Immunodeficiency Virus 1 (HIV-1) and HIV-2 diagnostic assays and structural studies


Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Monkeypox; 3 months on

It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern.   What have we learned about this virus...

COVID-19 Underlines the Need for Universal Vaccines

This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...

Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis

This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...

The Continued Challenges of Flavivirus Serology

This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

9 + 12 =